Cited by 262SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Open access

Mizrahi, Barak, Lotan, Roni, Kalkstein, Nir, Peretz, Asaf, Perez, Galit, Ben-Tov, Amir, Chodick, Gabriel, Gazit, Sivan, Patalon, Tal·2021·Nature Communications

DOI 10.1038/s41467-021-26672-3PMC PMC8569006

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38–1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80–3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41467-021-26672-3

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Crude breakthrough infections by month of vaccination. The crude incidence rates per 10,000 individuals above the age of 16 are shown by the month of administration of the second dose of the vaccine; bars represent 95% confidence intervals.CC BY · PubMed Central

Fig. 2 Accumulative breakthorough infections and hospitalizations among Early and Late Vaccinnes during June - July 2021, Israel. Kaplan–Meier curves are used for the accumulative probability of breakthrough infection (a) and hospitalization (b) between June and July 2021 among individuals who were vaccinated Early (January to February 2021) compared with individuals who were vaccinated late (March to April 2021). X axis in curves a, b represents days from the start of the follow-up period (June 1, 2021). Shading illustrates 95% CIs (a, b).CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345
Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality
Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626

Show all 18 references

Sorted by citations

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Self-citation
Waning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807
Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Sachdeva, R., Gower, C., Ramsay, M., & Lopez Bernal, J. (2022) · Nature Medicine · doi:10.1038/s41591-022-01699-1 · Cited by 453
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283
Self-citation
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
Evans, J. P., Zeng, C., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., & Liu, S. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8057 · Cited by 239
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01575-4 · Cited by 222
Self-citation
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 211
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30884-6 · Cited by 143
Self-citation
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas, O., Warren, J. L., Crawford, F. W., Gazit, S., Patalon, T., Weinberger, D. M., & Pitzer, V. E. (2022) · Science · doi:10.1126/science.abl4292 · Cited by 153
Self-citation
Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study
Yadete, T., Batra, K., Netski, D. M., Antonio, S., Patros, M. J., & Bester, J. C. (2021) · Vaccines · doi:10.3390/vaccines9121424 · Cited by 162
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · doi:10.1101/2022.02.25.22271494 · Cited by 143
Self-citation
Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review
Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 145
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., & Weinberger, D. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7382 · Cited by 141
Self-citation
American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42372 · Cited by 129
COVID vaccine boosters: the most important questions
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-02158-6 · Cited by 109
COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study
Klugar, M., Riad, A., Mohanan, L., & Pokorná, A. (2021) · Vaccines · doi:10.3390/vaccines9121437 · Cited by 110
COVID-19 Vaccine Booster: To Boost or Not to Boost
Shekhar, R., Garg, I., Pal, S., Kottewar, S., & Sheikh, A. B. (2021) · Infectious Disease Reports · doi:10.3390/idr13040084 · Cited by 108
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Elslande, J. V., Oyaert, M., Lorent, N., Weygaerde, Y. V., Pottelbergh, G. V., Godderis, L., Ranst, M. A. V., André, E., Padalko, E. Y., Lagrou, K., et al. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115659 · Cited by 95
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 95
mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine
Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 90
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Kanokudom, S., Assawakosri, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10010086 · Cited by 82
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87
Self-citation
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 84
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 80
Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers
Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69
American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42109 · Cited by 69
Charge‐Polarized Selenium Vacancy in Nickel Diselenide Enabling Efficient and Stable Electrocatalytic Conversion of Oxygen to Hydrogen Peroxide
Wang, Y., Huang, H., Wu, J., Yang, H., Kang, Z., Liu, Y., Wang, Z., Menezes, P. W., & Chen, Z. (2022) · Advanced Science · doi:10.1002/advs.202205347 · Cited by 67
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63
Self-citation
Multiple COVID-19 Waves and Vaccination Effectiveness in the United States
Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 62
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 66
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 60
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
Bonelli, M. M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221558 · Cited by 61
The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben‐Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4130 · Cited by 55
Self-citation
Covid-19 booster vaccines: What we know and who’s doing what
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n2082 · Cited by 55
Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection
Keshavarz, B., Richards, N. E., Workman, L. J., Patel, J., Muehling, L. M., Canderan, G., Murphy, D. D., Brovero, S. G., Ailsworth, S. M., Eschenbacher, W. H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850987 · Cited by 53
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 55
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
Lapointe, H. R., Mwimanzi, F. M., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Speckmaier, S., Moran-Garcia, N., Datwani, S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac229 · Cited by 54
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 47
Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients
Benning, L., Morath, C. P., Bartenschlager, M., Kim, H., Reineke, M., Beimler, J., Buylaert, M., Nußhag, C., Kälble, F., Reichel, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17054 · Cited by 51
Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status
Yu, E. D., Wang, E. W., Garrigan, E., Goodwin, B., Sutherland, A., Tarke, A., Chang, J., Gálvez, R. I., Mateus, J., Ramirez, S. I., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.003 · Cited by 45
Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England
Mensah, A. A., Campbell, H., Stowe, J., Seghezzo, G., Simmons, R., Lacy, J., Bukasa, A., O’Boyle, S., Ramsay, M. E., Brown, K. E., et al. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00059-1 · Cited by 48
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 49
Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant–infected patients in Jiangsu, China
Hu, Z., Tao, B., Li, Z., Song, Y., Yi, C., Li, J., Zhu, M., Yi, Y., Huang, P., & Wang, J. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.030 · Cited by 47
Testing Fractional doses of COVID-19 Vaccines
Więcek, W., Ahuja, A., Chaudhuri, E., Kremer, M. R., Gomes, A. S., Snyder, C. M., Tabarrok, A. T., & Tan, B. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116932119 · Cited by 43
Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines
Hvidt, A. K., Baerends, E. A. M., Søgaard, O. S., Stærke, N. B., Raben, D., Reekie, J., Nielsen, H., Johansen, I. S., Wiese, L., Benfield, T., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.994160 · Cited by 43
Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study
McKeigue, P., McAllister, D., Hutchinson, S. J., Robertson, C., Stockton, D., & Colhoun, H. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00045-5 · Cited by 43
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases
Kappelman, M. D., Weaver, K. N., Zhang, X., Dai, X., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001619 · Cited by 42
GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults
Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39053-9 · Cited by 42
Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)
Basso, P., Negro, C., Cegolon, L., & Filon, F. L. (2022) · Viruses · doi:10.3390/v14020336 · Cited by 43
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 41
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose
Mwimanzi, F. M., Lapointe, H. R., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac199 · Cited by 40
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., et al. (2022) · medRxiv · doi:10.1093/cid/ciac404 · Cited by 35
Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose
Angel-Korman, A., Peres, E., Bryk, G., Lustig, Y., Indenbaum, V., Amit, S., Rapoport, V., Katzir, Z., Yagil, Y., Iaina, N. L., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab206 · Cited by 39
Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional survey
Noh, Y., Kim, J. H., Yoon, D., Choe, Y. J., Choe, S., Jung, J., Lee, S., & Shin, J. (2022) · Epidemiology and Health · doi:10.4178/epih.e2022061 · Cited by 35
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
Decru, B., Elslande, J. V., Steels, S., Pottelbergh, G. V., Godderis, L., Holm, B. V., Bossuyt, X., Weyenbergh, J. V., Maes, P., & Vermeersch, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909910 · Cited by 37
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers
Radner, H., Sieghart, D., Jorda, A., Fedrizzi, C., Hasenoehrl, T., Zdravkovic, A., Redlberger‐Fritz, M., Puchammer-Stoeckl, E., Anderle, K., Bergmann, F., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.12.008 · Cited by 32
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
Lechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30
Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021
Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.025 · Cited by 33
The association between social media use and hesitancy toward COVID-19 vaccine booster shots in China: A web-based cross-sectional survey
Wang, R., Qin, C., Du, M., Liu, Q., Tao, L., & Liu, J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2065167 · Cited by 36
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Schell, T. L., Knutson, K. L., Saha, S., Wald, A. M., Phan, H., Almasry, M., Chun, K., Grimes, I. C., Lutz, M. K., Hayney, M. S., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac082 · Cited by 33
Echinacea Purpurea For the Long-Term Prevention of Viral Respiratory Tract Infections During Covid-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study
Kolev, E., Mircheva, L., Edwards, M. R., Johnston, S. L., Kalinov, K., Stange, R., Gancitano, G., Berghe, W. V., & Kreft, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856410 · Cited by 31
COVID-19 forecasting using new viral variants and vaccination effectiveness models
Rashed, E. A., Kodera, S., & Hirata, A. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105986 · Cited by 31
Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era
Freund, O., Tau, L., Weiss, T. E., Zornitzki, L., Frydman, S., Jacob, G., & Bornstein, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268050 · Cited by 31
SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers
Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Pezzani, M. D., Lippi, G., Gibellini, D., Tacconelli, E., Vecchia, I. D., Sala, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081193 · Cited by 30
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 31
Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan
Kodera, S., Rashed, E. A., & Hirata, A. (2022) · Vaccines · doi:10.3390/vaccines10030430 · Cited by 28
Waning of 2-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection accounting for depletion-of-susceptibles bias
Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 32
Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women
Shen, C., Fu, Y.-C., Lin, Y.-P., Shen, C., Sun, D.-J., Shen, C., & Cheng, C. (2022) · Vaccines · doi:10.3390/vaccines10010101 · Cited by 27
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 27
COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
Yang, S. L., Ripen, A. M., Leong, C. T., Lee, J. V., Yen, C. H., Chand, A. K., Koh, K., Rahim, N. A. B. A., Gokilavanan, V., Mohamed, N. N. E., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2065936 · Cited by 28
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
Suntronwong, N., Yorsaeng, R., Puenpa, J., Auphimai, C., Thongmee, T., Vichaiwattana, P., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10030391 · Cited by 24
The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center
Skrzat‐Klapaczyńska, A., Bieńkowski, C., Kowalska, J. D., Paciorek, M., Puła, J., Krogulec, D., Stengiel, J., Pawełczyk, A., Perlejewski, K., Osuch, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10040552 · Cited by 27
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Ben‐Tov, A., Stuart, E. A., & Patalon, T. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00103-9 · Cited by 25
Self-citation
Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters
Leekha, A., Saeedi, A., Sefat, K. M. S. R., Kumar, M., Martinez-Paniagua, M. A., Damian, A., Kulkarni, R. S., Reichel, K., Rezvan, A., Masoumi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50133-2 · Cited by 25
Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2
Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21
Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge
Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Jang, Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208425120 · Cited by 23
Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea
Nham, E., Ko, J., Song, K., Choi, J., Kim, E. S., Kim, H., Kim, B., Lim, H.-Y., Kim, K.-C., Jang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968105 · Cited by 22
UVC-Based Air Disinfection Systems for Rapid Inactivation of SARS-CoV-2 Present in the Air
Garg, H., Ringe, R. P., Das, S., Parkash, S., Thakur, B., Delipan, R., Kumar, A., Kulkarni, K. S., Bansal, K., Patil, P. B., et al. (2023) · Pathogens · doi:10.3390/pathogens12030419 · Cited by 22
Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
Clairon, Q., Prague, M., Planas, D., Bruel, T., Hocqueloux, L., Prazuck, T., Schwartz, O., Thiébaut, R., & Guedj, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011282 · Cited by 25
Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2
Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 22
Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis
Mahumud, R. A., Ali, M. A., Kundu, S., Rahman, M. A., Kamara, J. K., & Renzaho, A. M. N. (2022) · Vaccines · doi:10.3390/vaccines10020277 · Cited by 20
SARS‐CoV‐2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine
Yavuz, E., Günal, Ö., Başbulut, E., & Şen, A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27794 · Cited by 19
Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections
Fan, Q., Shi, J., Yang, Y., Tang, G., Jiang, M., Li, J. J., Tang, J., Li, L., Wen, X., Zhang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31693-7 · Cited by 19
Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
Nguyen, D. C., Dao, T. L., Truong, T. M. D., Nguyen, T. H., Phan, T. N., Nguyen, M. H., Pham, T. D., Nguyen, X. B., Nguyen, T. B., & Hoang, V. T. (2022) · Vaccines · doi:10.3390/vaccines10081325 · Cited by 20
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era
Reedman, C. N., Drews, S. J., Yi, Q., Pambrun, C., & O’Brien, S. F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00339-22 · Cited by 20
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac315 · Cited by 22
Self-citation
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021
Muhsen, K., Maimon, N., Mizrahi, A., Varticovschi, B., Bodenheimer, O., Cohen, D., & Dagan, R. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.19940 · Cited by 18
Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20
Liu, M., Gan, H., Lin, Y., Lin, R., Xue, M., Zhang, T., Cheng, Z. J., & Sun, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192214663 · Cited by 19
Behavioral Intention and Its Predictors toward COVID-19 Booster Vaccination among Chinese Parents: Applying Two Behavioral Theories
Zhou, M., Liu, L., Gu, S., Peng, X., Zhang, C., Wu, Q.-F., Xu, X., & You, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127520 · Cited by 19
In vitro inhibition of SARS-CoV-2 Infection by dry algae powders
García-Ruíz, D., Villalobos-Sánchez, E., Alam-Escamilla, D., & Elizondo‐Quiroga, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-22148-6 · Cited by 21
Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China
Tang, S., Wang, X., Tang, B., He, S., Yan, D., Huang, C., Shao, Y., Xiao, Y., & Cheke, R. (2023) · BMC Public Health · doi:10.1186/s12889-023-16009-8 · Cited by 18
COVID-19 booster uptake among US adults: Assessing the impact of vaccine attributes, incentives, and context in a choice-based experiment
Raman, S., Kriner, D. L., Ziebarth, N. R., Simon, K. I., & Kreps, S. E. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.115277 · Cited by 18
Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study
Hitchings, M. D. T., Ranzani, O., Lind, M. L., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070102 · Cited by 18

Authors: Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S., & Patalon, T.
Affiliations: Maccabi Healthcare Services (IL)
Tel Aviv University (IL)
Corresponding author: Lotan, Roni
ORCID: Mizrahi, Barak
Lotan, Roni
Kalkstein, Nir
Peretz, Asaf
Ben-Tov, Amir
Chodick, Gabriel
Gazit, Sivan
Patalon, Tal
Venue: Nature Communications
Publisher: Springer Science and Business Media LLC
Published: 2021-11-04
Volume: 12
Issue: 1
Pages: 6379-6379
ISSN: 2041-1723 (ISSN-L)
DOI: 10.1038/s41467-021-26672-3
PMC: PMC8569006
OpenAlex: W3209833474
Cited by: 261
References: 18
Citations by year: 2026: 1 · 2025: 4 · 2024: 18 · 2023: 55 · 2022: 140 · 2021: 43
FWCI: 20.35
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Communications (publishedVersion, cc-by)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: SARS-CoV-2, breakthrough infection, BNT162b2, mRNA vaccines, vaccine waning, time since vaccination, long-term vaccine effectiveness, COVID-19 pandemic, Maccabi Healthcare Services
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Time Factors, Vaccination, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks